{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T13:54:26Z","timestamp":1793022866555,"version":"4.5.0"},"reference-count":38,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2018,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Although carbapenems are effective for treating serious multidrug-resistant\n            <jats:named-content content-type=\"genus-species\">Pseudomonas aeruginosa<\/jats:named-content>\n            infections, carbapenem-resistant\n            <jats:named-content content-type=\"genus-species\">P. aeruginosa<\/jats:named-content>\n            (CRPA) is now being reported worldwide. Ceftolozane-tazobactam (C\/T) demonstrates activity against many multidrug-resistant isolates. We evaluated the activity of C\/T and compared its activity to that of ceftazidime-avibactam (C\/A) using a well-characterized collection of non-carbapenemase-producing CRPA isolates. Forty-two non-carbapenemase-producing CRPA isolates from a previous study (J. Y. Lee and K. S. Ko, Int J Antimicrob Agents 40:168\u2013172, 2012,\n            <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/doi.org\/10.1016\/j.ijantimicag.2012.04.004\">https:\/\/doi.org\/10.1016\/j.ijantimicag.2012.04.004<\/jats:ext-link>\n            ) were included. All had been previously shown to be negative for\n            <jats:italic>bla<\/jats:italic>\n            <jats:sub>IMP<\/jats:sub>\n            ,\n            <jats:italic>bla<\/jats:italic>\n            <jats:sub>VIM<\/jats:sub>\n            ,\n            <jats:italic>bla<\/jats:italic>\n            <jats:sub>SPM<\/jats:sub>\n            ,\n            <jats:italic>bla<\/jats:italic>\n            <jats:sub>GIM<\/jats:sub>\n            ,\n            <jats:italic>bla<\/jats:italic>\n            <jats:sub>SIM<\/jats:sub>\n            , and\n            <jats:italic>bla<\/jats:italic>\n            <jats:sub>KPC<\/jats:sub>\n            by PCR. In the prior study, expression of\n            <jats:italic>oprD<\/jats:italic>\n            ,\n            <jats:italic>ampC<\/jats:italic>\n            , and several efflux pump genes had been defined by quantitative reverse transcription-PCR. Here, antimicrobial susceptibility was determined by broth microdilution according to Clinical and Laboratory Standards Institute (CLSI) guidelines. Time-kill curve assays were performed using three C\/T- and C\/A-susceptible CRPA isolates. Among 42 non-carbapenemase-producing CRPA isolates, overall susceptibility to C\/T was 95.2%, compared to 71.4%, 42.9%, 23.8%, 21.4%, and 2.4% for C\/A, ceftazidime, piperacillin-tazobactam, cefepime, and meropenem, respectively. The C\/T resistance rate was significantly lower than that of C\/A among isolates showing decreased\n            <jats:italic>oprD<\/jats:italic>\n            and increased\n            <jats:italic>mexB<\/jats:italic>\n            expression (5.1% versus 25.6%,\n            <jats:italic>P<\/jats:italic>\n            = 0.025, and 4.3% versus 34.8%,\n            <jats:italic>P<\/jats:italic>\n            = 0.022, respectively). In time-kill curve studies, C\/T was less bactericidal than C\/A against an isolate with decreased\n            <jats:italic>oprD<\/jats:italic>\n            and increased\n            <jats:italic>ampC<\/jats:italic>\n            expression. C\/T was active against 95.2% of non-carbapenemase-producing CRPA clinical isolates. No apparent correlation of C\/T MIC values with specific mutation-driven resistance mechanisms was noted.\n          <\/jats:p>","DOI":"10.1128\/aac.01970-17","type":"journal-article","created":{"date-parts":[[2017,11,13]],"date-time":"2017-11-13T16:39:15Z","timestamp":1510591155000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":53,"title":["Activity of Ceftolozane-Tazobactam against Carbapenem-Resistant, Non-Carbapenemase-Producing Pseudomonas aeruginosa and Associated Resistance Mechanisms"],"prefix":"10.1128","volume":"62","author":[{"given":"Yu Mi","family":"Wi","sequence":"first","affiliation":[{"name":"Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA"},{"name":"Division of Infectious Diseases, Department of Medicine, Samsung Changwon Hospital, Sungkyunkwan University, Changwon, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerryl E.","family":"Greenwood-Quaintance","sequence":"additional","affiliation":[{"name":"Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey N.","family":"Schuetz","sequence":"additional","affiliation":[{"name":"Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwan Soo","family":"Ko","sequence":"additional","affiliation":[{"name":"Department of Molecular Cell Biology, Sungkyunkwan University School of Medicine, Suwon, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyong Ran","family":"Peck","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Hoon","family":"Song","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6344-4141","authenticated-orcid":false,"given":"Robin","family":"Patel","sequence":"additional","affiliation":[{"name":"Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA"},{"name":"Division of Infectious Diseases, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1985.00360090089015"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2011.00065"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/49.2.229"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2017.01.023"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.5.1085"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2012.04.004"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.9.2046"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2013.11.014"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00257-10"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2014.0172"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2009.03.021"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-013-0168-2"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw243"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2017.09.001"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00054-17"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00750-12"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.4.1306-1311.2005"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0000000000000109"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2016.05.011"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01404-13"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01802-13"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2014.04.004"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2014.01.032"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04238-14"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02462-13"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00825-15"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03681-14"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M113.485979"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1205073109"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2003.11.007"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr045"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/19.6.733"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/12.2.119"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00040-09"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00965-13"},{"key":"e_1_3_2_37_2","volume-title":"CLSI document M100-S27","author":"Clinical and Laboratory Standards Institute","year":"2017","unstructured":"Clinical and Laboratory Standards Institute. 2017. Performance standards for antimicrobial susceptibility testing: 27th informational supplement. CLSI document M100-S27. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01645-10"},{"key":"e_1_3_2_39_2","volume-title":"CLSI document M07-A10","author":"Clinical and Laboratory Standards Institute","year":"2015","unstructured":"Clinical and Laboratory Standards Institute. 2015. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard\u201410th ed. CLSI document M07-A10. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"10"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01970-17","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01970-17","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:07:23Z","timestamp":1645477643000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01970-17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["10.1128\/AAC.01970-17"],"URL":"https:\/\/doi.org\/10.1128\/aac.01970-17","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"2017-09-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-11-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-12-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01970-17"}}